Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566
Artículo
![Thumbnail](/themes/Mirage2/images/cubierta.jpg)
Open/ Download
Access note
Acceso a solo metadatos
Publication date
2017Metadata
Show full item record
Cómo citar
Deacon, R. M. J.
Cómo citar
Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566
Author
Abstract
Fragile X-associated disorders are a family of genetic conditions resulting from the partial or complete loss of fragile X mental retardation protein (FMRP). Among these disorders, fragile X syndrome (FXS) is the most common cause of inherited intellectual disability and autism. Progress in basic neuroscience has led to identification of molecular targets for treatment in FXS; however, there is a gap in translation to targeted therapies in humans. This study introduces a novel therapeutic target for FXS, nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor known to induce expression of over 100 cytoprotective genes. We also show that NNZ2566, a drug that has successfully completed a phase 2 clinical trial in FXS, is effective in modulating this target in FXS, partially reversing the FXS phenotype; NNZ2566 has a therapeutic role as Nrf2 activator. Effectively, treatment with NNZ2566 normalizes the translocation of Nrf2 to the nucleus, inducing expression of numerous oxidative stress-related genes including NQO1 (NAD(P) H dehydrogenase quinone 1), GST-alpha 1 (glutathione S-transferase alpha-1) and EH (epoxide hydrolase) and has a knockdown effect on E-cadherin. In summary, the Nrf2/ARE (antioxidant response element) pathway appears to be a novel promising therapeutic target for FXS and NNZ2566 appears to be acting as an activator of the Nrf2/ARE pathway and suggests a potential benefit across multiple symptoms that could be associated with the pathobiological processes underlying FXS.
Patrocinador
FRAXA Research Foundation Neuren Pharmaceuticals Ltd NNZ2566
Indexation
Artículo de publicación ISI
Quote Item
Genes Brain and Behavior 16 (7) : 1-10
Collections